Custom Search

Monday, July 18, 2011

chronic obstructive pulmonary disease COPD New drug molecule for treatment of

Arcapta Neohaler a new drug for treatment of chronic obstructive pulmonary disease.

Chronic obstructive pulmonary disease (COPD) is a long term lung disease where in patients face lot of difficulty in breathing and unfortunately so far there is no cure for COPD, we can treat the symptoms and provide symptomatic relief to patient suffering from (COPD) by treating symptoms with appropriate drug.

Chronic obstructive pulmonary disease (COPD) can be classified as
1. Chronic bronchitis, long-term coughs with mucus.
2. Emphysema, destruction of the lungs over time
3. Many patients affected with COPD may show both Chronic bronchitis and Emphysema.

Causes of COPD are as follows :
Inhalation of certain gases or fumes of chemicals, pollution and secondary smoke, cigarette smoking ,

Symptoms of COPD are as follows :
Breathlessness , fatigue , respiratory infections, wheezing

Now there is a new drug molecule approved by US FDA brand name of the drug is Arcapta Neohaler (Indacaterol inhalation powder) to treat patient suffering from COPD including Emphysema and chronic bronchitis.
Arcapta Neohaler (indacaterol) is a beta2-adrenergic agonist which brings about relaxation in muscles around air way to lungs , lungs to remain in a relaxed position so that the patient get relief from wheezing and breathlessness.


Arcapta Neohaler (Indacaterol inhalation powder) is given once in a day as maintenance bronchodilator treatment of airflow obstruction to patients affected with COPD rather Arcapta Neohaler provides a long term treatment option for COPD patients to get relive from breathlessness.
Safty warning :
Arcapta Neohaler carries boxed warning as log term adrenergic agonists (LABA) increase the risk of asthma-related death log term adrenergic agonists should not be used in patients suffering from log term adrenergic agonists unless used with a long-term asthma control drugs

Arcapta Neohaler is not for treating sudden attacks of asthma and sever form of COPD.


Side effects include: headache and nausea, runny nose, cough, sore throat.
 
Novartis Pharmaceuticals Corp. of East Hanover, N.J. is marketing drug Arcapta Neohaler.


Also see

What is blow fill seal technology in sterile dosage form


Aspects of Validation of Aseptic Process and Sterilisation , Sterilization of Equipment, Containers, and Closures

What is pharmaceutical product information manual (Pharmaceutical product dossier) for registration of  pharmaceutical product to foreign countries

US FDA limits dosage of acetaminophen to 325 mg per unit dosage form,Requires boxed warning on lables

What is an Isolator in pharmaceutical manufacturing

What is a Laminar Air Flow Cabinet?

21 cfr part 11 FDA guidelines .

Media Fill Run To Ensure Sterility In Sterile Dosage Forms

What is HEPA filter?

 Jobs in Pharma company Find best Pharma sales job

No comments:

Posted by: Martin

How to sucessfuly activate and receive our articles on pharmaceuticals by E-Mail

Dear readers if you wish to receive our articles on pharmaceutical automatically into your email Inbox , as and when we write a new article over this website, then follow these 3 simple steps.


1.You should write your Email ID in the box provided and push the subscribe butten


2.Enter the text code that we show you in a small new browser window after you enter your email ID.

3.Log in to your email and Cheke our verification email sent by "FEEDBURNER" , there you should verify the link we send you by email.




Enter your email address get our articles by email whenever this website is updated





Delivered by FeedBurner



Join the list of our readers from Universities ,Research and Development centers Pharmaceutical Companies from all over the world.











Pharma Research Regulatory Guidelines Website
Texas Dallas, TX 75211 US
Email: editor@pharmacistspharmajournal.org Website: http://pharmacistspharmajournal.org/
Copyright © 2008-2015 all rights reserve www.pharmacistspharmajournal.org